New combo therapy shows promise for Hard-to-Treat gut cancer
NCT ID NCT04258956
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a combination of two drugs—avelumab (an immunotherapy) and axitinib (a targeted therapy)—in 58 adults with advanced gastrointestinal stromal tumor (GIST) that had worsened after standard treatments. The main goal was to see how many patients were still cancer-free at 3 months. The trial is now complete, and results will help determine if this combination is worth further study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avelumab (immunotherapy) and axitinib (targeted therapy)
What this could lead to
If successful, this combination could offer a new treatment option for advanced GIST patients who have run out of standard therapies.
What could go wrong
This is a small, single-arm Phase 2 trial with no comparison group, so results may not be definitive. The combination may cause side effects like fatigue, high blood pressure, or immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Maria Sklodowska-Curie National Research Institue of Oncology
Warsaw, 02-781, Poland